Trials / Completed
CompletedNCT00704665
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
A Randomized, Double-Blind, Placebo-Controlled Trial of Recombinant Human Relaxin in the Treatment of Systemic Sclerosis With Diffuse Scleroderma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 231 (actual)
- Sponsor
- University of Medicine and Dentistry of New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in pregnancy. Study is designed to see if skin improvement and improvement in functional ability can be achieved.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Relaxin | 10 ug/kg/day or 25 ug/kg/day |
| DRUG | Relaxin | Placebo |
Timeline
- Start date
- 1998-12-01
- Primary completion
- 2001-12-01
- Completion
- 2001-12-01
- First posted
- 2008-06-25
- Last updated
- 2008-06-25
Source: ClinicalTrials.gov record NCT00704665. Inclusion in this directory is not an endorsement.